文献速递乳腺癌放疗

EORTC 22925/10925试验:I-III期乳腺癌区域淋巴结照射——不同局部区域和全身治疗下的结局

The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.
PubMed 文献 · Radiother Oncol · 2024-09-26

该试验旨在评估选择性内乳和锁骨上内侧(IM-MS)放疗对I-III期乳腺癌总生存的影响,中位随访15.7年,共纳入4004例患者。探索性分析显示不同局部区域和全身治疗方式与首发事件部位相关,IM-MS放疗在分层敏感性分析中显著减少区域复发并改善无病生存。

要点

  • 中位随访15.7年,4004例患者中16%未接受术后全身治疗,30%仅内分泌治疗,25%仅化疗,30%化疗联合内分泌治疗。
  • 乳房切除术(伴或不伴术后放疗)较保乳治疗局部控制更好,但以远处转移为首发事件更多。
  • 保乳治疗接受瘤床加量者及接受低位腋窝放疗者以远处转移为首发事件更多。

核心结论

  • 不同治疗组成部分影响首发事件部位,IM-MS放疗在不同乳腺癌结局中的改善最可能与试验分组和分层方法使各组均衡有关。

研究设计与样本

  • 手术、胸壁放疗、保乳术后瘤床加量、腋窝放疗及全身治疗均按医生偏好选择。
  • 采用Cox模型或Fine & Gray竞争风险模型分析局部区域和全身治疗类型对乳腺癌结局的影响,校正基线患者和疾病特征及治疗,显著性水平为5%(双侧)。

主要发现

  • 625例(16%)未接受术后全身治疗,1185例(30%)仅内分泌治疗,994例(25%)仅化疗,1200例(30%)化疗联合内分泌治疗,随机分组间无差异。
  • 治疗的实施和类型与年龄、绝经状态、临床T和N分期及ER状态相关(p < 0.0001)。
  • 乳房切除术(伴或不伴术后放疗)较保乳治疗局部控制更好,但乳房切除术以远处转移为首发事件更多。
  • 保乳治疗接受瘤床加量者及接受低位腋窝放疗者以远处转移为首发事件更多。
  • IM-MS放疗在分层敏感性分析中显著减少区域复发并改善无病生存;乳房切除术较保乳治疗总生存更差,腋窝放疗总生存更差,而前哨淋巴结清扫和辅助化疗联合内分泌治疗总生存更好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The EORTC 22922/10925 trial aimed to investigate the impact on overall survival (OS) of elective internal mammary and medial supraclavicular (IM-MS) radiation therapy (RT) in breast cancer stage I-III. Surgery for the primary tumour and axillary lymph nodes, chest wall RT, boost RT after whole breast RT in breast conserving therapy (BCT), RT to operated axilla, and systemic therapy were per physician's preference. The aim of the current analysis is to assess breast cancer outcomes according to different locoregional and systemic therapy used in the trial. MATERIAL/METHODS: Data with a median follow-up of 15.7 years were extracted from the trial's case report forms. Kaplan-Meier curves of disease-free and OS and cumulative incidence curves of breast cancer events were produced. An exploratory analysis of the effect of the type of locoregional and systemic therapy on breast cancer outcomes was conducted using the Cox model or the Fine & Gray model accounting for competing risks, both models being adjusted for baseline patient and disease characteristics and treatment. The significance level was set at 5 %, 2-sided. RESULTS: Of the 4,004 patients included, 625 (16%) did not receive any postoperative systemic therapy, 1,185 (30%) received endocrine therapy only, 994 (25%) chemotherapy only, and 1,200 (30%) both chemotherapy and endocrine therapy, without differences between the randomisation arms. Administration and type of therapy was associated with age, menopausal status, clinical T- and N-stage and ER status (p < 0.0001). Local control was better with mastectomy (with/without postmastectomy RT) as compared to BCT, but mastectomy was associated with more distant metastasis (DM) as first event. Similarly, DM as first event occurred more in the BCT group that received a boost as compared to no boost and in those who received RT to the lower axillary level. IM-MS RT reduced significantly regional recurrences and improved disease-free survival in a sensitivity stratified analysis. OS was worse with mastectomy as compared to BCT and with irradiation of the axilla but better with sentinel node dissection and adjuvant combined chemo and hormonal therapy. CONCLUSION: Different components of therapy influenced the site of first event. IM-MS RT improved outcomes in different breast cancer outcomes were most probably related that the group were balanced due to the trial arms and stratification methods.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kaidar-Person O, Boersma LJ, De Brouwer P, et al. The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies. Radiother Oncol. 2024. PMID: 39341505. doi:10.1016/j.radonc.2024.110563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。